Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2015

01.04.2015 | original report

New drugs on the horizon. Treatment of myeloma in 2020, a perspective

verfasst von: Prof. Dr. Heinz Ludwig, Wolfgang Hilbe, Niklas Zojer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

This minireview covers novel drugs and treatment concepts being evaluated in early studies for therapy of patients with multiple myeloma (MM). Panobinostat, a histone deacetylase inhibitor, showed limited improvement in progression-free survival, thus raising doubt whether these substances will provide clinical meaningful benefits in MM. Some of the new proteasome inhibitors beyond carfilzomib offer the benefit of oral administration and reduced neurotoxicity. Monoclonal antibodies with antimyeloma or antistroma cell activity raise expectations for improved treatment outcome when combined with conventional chemotherapy. A series of new inhibitors of signal pathways important for proliferation and progression in MM presently are scrutinized for their clinical usefulness. Among these, inhibitors of the mitogen activated protein kinase (MAPK), epidermal growth factor receptor (EGFR), protein kinase B (AKT), and B-cell receptor pathway as well as drugs inhibiting the spindle protein, Bcl-2, and cyclin-dependent kinases show promise for becoming important antimyeloma dugs. Checkpoint inhibitors have shown significant activity in some solid tumors and are now tested in MM as well. Measles viruses bind via CD46 to myeloma cells, self-amplify at sites of tumor growth, and induce cell death in myeloma but not in normal cells, thus offering a completely new treatment strategy. However, before introduction of these interesting approaches into the clinic, confirmation of their clinical efficacy is needed.
Literatur
1.
Zurück zum Zitat San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicenter, randomized, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–206. CrossRefPubMed San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicenter, randomized, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–206. CrossRefPubMed
2.
Zurück zum Zitat Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014;124(7):1047–55. CrossRefPubMed Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014;124(7):1047–55. CrossRefPubMed
3.
Zurück zum Zitat Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008;111(3):1654–64. CrossRefPubMedCentralPubMed Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008;111(3):1654–64. CrossRefPubMedCentralPubMed
4.
Zurück zum Zitat Anderson KC. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012;30(4):445–52. CrossRefPubMed Anderson KC. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012;30(4):445–52. CrossRefPubMed
5.
Zurück zum Zitat Richardson PG, Jagannath S, Moreau Ph, et al. Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 2014. Abstract 302 (ASH Annual Meeting Abstracts). Richardson PG, Jagannath S, Moreau Ph, et al. Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 2014. Abstract 302 (ASH Annual Meeting Abstracts).
6.
Zurück zum Zitat de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–8. CrossRefPubMed de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–8. CrossRefPubMed
7.
Zurück zum Zitat Lokhorst H, Laubach J, Nahi H, et al. Dose-dependent efficacy of Daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM). EHA 2014:Abstract P356. Lokhorst H, Laubach J, Nahi H, et al. Dose-dependent efficacy of Daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM). EHA 2014:Abstract P356.
8.
Zurück zum Zitat Gang A, Hua J, Chirag A, et al. SAR 650984, a therapeutic anti-CD38 monoclonal antibody, blocks CD38-CD31 interaction in multiple myeloma. Blood. 2014:Abstract 4729 (ASH Annual Meeting Abstracts). Gang A, Hua J, Chirag A, et al. SAR 650984, a therapeutic anti-CD38 monoclonal antibody, blocks CD38-CD31 interaction in multiple myeloma. Blood. 2014:Abstract 4729 (ASH Annual Meeting Abstracts).
9.
Zurück zum Zitat Mateos MV, Cibeira MT, Richardson PG, et al. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res. 2010;16(12):3260–9. CrossRefPubMed Mateos MV, Cibeira MT, Richardson PG, et al. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res. 2010;16(12):3260–9. CrossRefPubMed
10.
Zurück zum Zitat Shah JJ, Zonder JA, Cohen A, et al. The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: results from a phase 2 study. Blood. 2012;120:Abstract 449 (ASH Annual Meeting Abstracts). Shah JJ, Zonder JA, Cohen A, et al. The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: results from a phase 2 study. Blood. 2012;120:Abstract 449 (ASH Annual Meeting Abstracts).
11.
Zurück zum Zitat Lonial S, Shah JJ, Zonder J, et al. Prolonged survival and improved response rates with ARRY-520 In relapsed/refractory multiple myeloma (RRMM) patients with low α-1 acid glycoprotein (AAG) levels: results from a phase 2 study. Blood. 2013;122:285 (ASH Annual Meeting Abstracts). CrossRef Lonial S, Shah JJ, Zonder J, et al. Prolonged survival and improved response rates with ARRY-520 In relapsed/refractory multiple myeloma (RRMM) patients with low α-1 acid glycoprotein (AAG) levels: results from a phase 2 study. Blood. 2013;122:285 (ASH Annual Meeting Abstracts). CrossRef
12.
Zurück zum Zitat Spencer A, Yoon SS, Harrison SJ, et al. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014;124(14):2190–5. Spencer A, Yoon SS, Harrison SJ, et al. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014;124(14):2190–5.
13.
Zurück zum Zitat Santra M, Zhan F, Tian E, et al. A subset of multiple myeloma harboring the t(4; 14)(p16; q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood. 2003;101(6):2374–6. CrossRefPubMed Santra M, Zhan F, Tian E, et al. A subset of multiple myeloma harboring the t(4; 14)(p16; q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood. 2003;101(6):2374–6. CrossRefPubMed
14.
Zurück zum Zitat Trudel S, Ely S, Farooqi Y, et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood. 2004;103(9):3521–8. CrossRefPubMed Trudel S, Ely S, Farooqi Y, et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood. 2004;103(9):3521–8. CrossRefPubMed
15.
Zurück zum Zitat Xin X, Abrams TJ, Hollenbach PW, et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res. 2006;12(16):4908–15. CrossRefPubMed Xin X, Abrams TJ, Hollenbach PW, et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res. 2006;12(16):4908–15. CrossRefPubMed
16.
Zurück zum Zitat Sharkey J, Khong T, Spencer A. PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells. Blood. 2007;109(4):1712–9. CrossRefPubMed Sharkey J, Khong T, Spencer A. PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells. Blood. 2007;109(4):1712–9. CrossRefPubMed
17.
Zurück zum Zitat Andrulis M, Lehners N, Capper D, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3(8):862–9. CrossRefPubMed Andrulis M, Lehners N, Capper D, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3(8):862–9. CrossRefPubMed
18.
Zurück zum Zitat Yordanova A, Hose D, Neben K, et al. Sorafenib in patients with refractory or recurrent multiple myeloma. Hematol Oncol. 2013;31(4):197–200. CrossRefPubMed Yordanova A, Hose D, Neben K, et al. Sorafenib in patients with refractory or recurrent multiple myeloma. Hematol Oncol. 2013;31(4):197–200. CrossRefPubMed
19.
Zurück zum Zitat Srkalovic G, Hussein MA, Hoering A, et al. A phase II trial of BAY 43–9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med. 2014;3(5):1275–83. CrossRefPubMedCentralPubMed Srkalovic G, Hussein MA, Hoering A, et al. A phase II trial of BAY 43–9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med. 2014;3(5):1275–83. CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat Sharman JP, Chmielecki J, Morosini D, et al. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14(5):e161–3. CrossRefPubMed Sharman JP, Chmielecki J, Morosini D, et al. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14(5):e161–3. CrossRefPubMed
21.
Zurück zum Zitat Vij R, Huff CA, Bensinger WI, et al. Ibrutinib, single agent or in combination with dexamethasone, in patients with relapsed or relapsed/refractory multiple myeloma (MM): preliminary phase 2 results. Blood. 2014:Abstract 31 (ASH Annual Meeting Abstracts). Vij R, Huff CA, Bensinger WI, et al. Ibrutinib, single agent or in combination with dexamethasone, in patients with relapsed or relapsed/refractory multiple myeloma (MM): preliminary phase 2 results. Blood. 2014:Abstract 31 (ASH Annual Meeting Abstracts).
22.
Zurück zum Zitat Kumar SK, LaPlant B, Chng WJ, et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015;125(3):443-8. Kumar SK, LaPlant B, Chng WJ, et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015;125(3):443-8.
23.
Zurück zum Zitat Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210–2. CrossRefPubMedCentralPubMed Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210–2. CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. CrossRefPubMedCentralPubMed Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Curr Opin Mol Ther. 2010;12(6):724–33. PubMed Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Curr Opin Mol Ther. 2010;12(6):724–33. PubMed
26.
Zurück zum Zitat Benson DM, Cohen AD, Hofmeister CC, et al. A phase I trial of Anti-KIR monoclonal antibody IPH2101 and lenalidomide for multiple myeloma. Blood. 2013;122:3181 (ASH 2013 Annual Meeting Abstracts). Benson DM, Cohen AD, Hofmeister CC, et al. A phase I trial of Anti-KIR monoclonal antibody IPH2101 and lenalidomide for multiple myeloma. Blood. 2013;122:3181 (ASH 2013 Annual Meeting Abstracts).
27.
Zurück zum Zitat Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044–51. CrossRefPubMed Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044–51. CrossRefPubMed
28.
Zurück zum Zitat Russell SJ, Federspiel MJ, Peng KW, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc. 2014;89(7):926–33. CrossRefPubMedCentralPubMed Russell SJ, Federspiel MJ, Peng KW, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc. 2014;89(7):926–33. CrossRefPubMedCentralPubMed
Metadaten
Titel
New drugs on the horizon. Treatment of myeloma in 2020, a perspective
verfasst von
Prof. Dr. Heinz Ludwig
Wolfgang Hilbe
Niklas Zojer
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0194-0

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe